Atnahs Acquires Naproxen Suspension in the US

11th May 2016

Basildon, UK, May 11 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce that the Food and Drug Administration (“FDA”) has granted supplement approval to the manufacturing site transfer of Naproxen Suspension in the US.

This has triggered the second and final US$ 2 million payment in a total transaction of US$4.25 million.